teensexonline.com

Chemed (CHE) Lags Q3 Earnings and Income Estimates

Date:

Chemed (CHE) got here out with quarterly earnings of $5.64 per share, lacking the Zacks Consensus Estimate of $5.76 per share. This compares to earnings of $5.32 per share a yr in the past. These figures are adjusted for non-recurring objects.

This quarterly report represents an earnings shock of -2.08%. 1 / 4 in the past, it was anticipated that this operator of the Roto-Rooter plumbing service and Vitas Healthcare hospices would publish earnings of $5.54 per share when it truly produced earnings of $5.47, delivering a shock of -1.26%.

During the last 4 quarters, the corporate has surpassed consensus EPS estimates simply as soon as.

Chemed, which belongs to the Zacks Medical – Outpatient and Dwelling Healthcare business, posted revenues of $606.18 million for the quarter ended September 2024, lacking the Zacks Consensus Estimate by 1.12%. This compares to year-ago revenues of $564.53 million. The corporate has topped consensus income estimates simply as soon as over the past 4 quarters.

The sustainability of the inventory’s speedy worth motion primarily based on the recently-released numbers and future earnings expectations will largely rely upon administration’s commentary on the earnings name.

Chemed shares have added about 4.1% for the reason that starting of the yr versus the S&P 500’s achieve of twenty-two.1%.

What’s Subsequent for Chemed?

Whereas Chemed has underperformed the market up to now this yr, the query that involves traders’ minds is: what’s subsequent for the inventory?

There aren’t any simple solutions to this key query, however one dependable measure that may assist traders deal with that is the corporate’s earnings outlook. Not solely does this embody present consensus earnings expectations for the approaching quarter(s), but additionally how these expectations have modified currently.

Empirical analysis reveals a robust correlation between near-term inventory actions and developments in earnings estimate revisions. Traders can monitor such revisions by themselves or depend on a tried-and-tested ranking device just like the Zacks Rank, which has a powerful monitor document of harnessing the facility of earnings estimate revisions.

Forward of this earnings release, the estimate revisions pattern for Chemed: blended. Whereas the magnitude and course of estimate revisions might change following the corporate’s just-released earnings report, the present standing interprets right into a Zacks Rank #3 (Maintain) for the inventory. So, the shares are anticipated to carry out according to the market within the close to future. You’ll be able to see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Will probably be fascinating to see how estimates for the approaching quarters and present fiscal yr change within the days forward. The present consensus EPS estimate is $7.05 on $641.75 million in revenues for the approaching quarter and $23.58 on $2.44 billion in revenues for the present fiscal yr.

Traders ought to be conscious of the truth that the outlook for the business can have a cloth influence on the efficiency of the inventory as nicely. By way of the Zacks Business Rank, Medical – Outpatient and Dwelling Healthcare is at the moment within the high 9% of the 250 plus Zacks industries. Our analysis reveals that the highest 50% of the Zacks-ranked industries outperform the underside 50% by an element of greater than 2 to 1.

One different inventory from the identical business, U.S. Bodily Remedy (USPH), is but to report outcomes for the quarter ended September 2024. The outcomes are anticipated to be launched on November 5.

This doctor staffing companies firm is anticipated to publish quarterly earnings of $0.68 per share in its upcoming report, which represents a year-over-year change of +9.7%. The consensus EPS estimate for the quarter has been revised 3.1% decrease over the past 30 days to the present stage.

U.S. Bodily Remedy’s revenues are anticipated to be $163.97 million, up 9.3% from the year-ago quarter.

Ought to You Spend money on Chemed Company (CHE)?

Earlier than you put money into Chemed Company (CHE), need to know the most effective shares to purchase for the subsequent 30 days? Try Zacks Funding Analysis for our free report on the 7 best stocks to purchase.

Zacks Funding Analysis has been dedicated to offering traders with instruments and impartial analysis since 1978. For greater than 1 / 4 century, the Zacks Rank stock-rating system has greater than doubled the S&P 500 with a mean achieve of +24.08% per yr. (These returns cowl a interval from January 1, 1988 by Could 6, 2024.)

Want the latest recommendations from Zacks Investment Research? Today, you can download 5 Stocks Set to Double. Click to get this free report

Chemed Corporation (CHE) : Free Stock Analysis Report

U.S. Physical Therapy, Inc. (USPH) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the creator and don’t essentially replicate these of Nasdaq, Inc.

Share post:

Subscribe

Popular

More like this
Related